Taking the pooled standard deviation into account, this results in a Cohen’s d of 0.24 (males vs females), 0.43 (COVID-19 patients with or without cardiovascular disease), and 0.27 (COVID-19 patients with or without respiratory disease) for orexin A, indicating a small to medium effect (Table 2). Here, HCRT is linked to respiratory system disorder.